← All stocks

COLLEGIUM PHARMACEUTICAL, INC

COLL Mostly scheduled
CIK 0001267565 #2677 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$7.25M
$3.95M on a plan · $2.96M straight out of an exercise
Sold at will
$334.22K
3 of 14 sales
Net
−$7.25M
−$334.22K against sales at will

By person

16 insiders · 15 transactions

There is no salary here to measure against. COLLEGIUM PHARMACEUTICAL, INC's chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Dreyer Scott
EVP & Chief Commercial Officer
$2.87M (4) scheduled
−$2.87M
71,770
0.2205%
$2.44M
−32.2%
Fallon John A.
Director
$1.65M (1) scheduled
−$1.65M
64,634
0.1985%
$2.20M
+17.9%
Tupper Colleen
EVP & Chief Financial Officer
$1.22M (2) scheduled
−$1.22M
147,282
0.4524%
$5.01M
+12.6%
Dieter David
EVP & General Counsel
$716.21K (2) scheduled
−$716.21K
77,071
0.2367%
$2.62M
+733.7%
BOHLIN GAREN G
Director
$323.49K (1) scheduled
−$323.49K
71,000
0.2181%
$2.42M
+35.3%
Balice-Gordon Rita J.
Director
$171.67K (1)
−$171.67K
61,370
0.1885%
$2.09M
+32.0%
Lurker Nancy
Director
$161.86K (1)
−$161.86K
26,758
0.0822%
$911.11K
Freund John Gordon
Director
$143.23K (2) scheduled
−$143.23K
107,081
0.3289%
$3.65M
+22.7%
Rubric Capital Management LP entity
10% owner
3,132,743
9.62%
$106.67M
−0.8%
Karnani Vikram
President and CEO
197,864
0.6078%
$6.74M
+52,523%
SANTINI GINO
Director
112,483
0.3455%
$3.83M
+48.7%
Kuhlmann Shirley R.
EVP and General Counsel
108,137
0.3322%
$3.68M
−9.3%
Smith Thomas B
EVP and Chief Medical Officer
90,651
0.2784%
$3.09M
+63.8%
Heffernan Michael Thomas
Director
50,328
0.1546%
$1.71M
+10.6%
Paya Carlos V
Director
28,323
0.0870%
$964.40K
Glancy Donovan Michael
Director
17,482
0.0537%
$595.26K
Insider
Date
Role
Action
Shares
Price
Amount
Freund John Gordon
15 May 2026
Director
Sold after exercise
4,127
$34.54
$142.55K
BOHLIN GAREN G
11 May 2026
Director
Sold after exercise
8,700
$37.18
$323.49K
Dreyer Scott
8 Dec 2025
EVP & Chief Commercial Officer
Sold after exercise
6,475
$48.66
$315.08K
Dreyer Scott
8 Dec 2025
EVP & Chief Commercial Officer
Sold after exercise
11,125
$47.89
$532.77K
Fallon John A.
12 Nov 2025
Director
Sold after exercise
34,853
$47.21
$1.65M

What was left out

Form 4 filings counted 25
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 6
Sales straight out of an exercise 5
Sales at will 3
Transactions with no price 0
Shares from compensation/vesting 556,864
History held since 2 Feb 2017